

UNIVERSIDADE ESTADUAL DE CAMPINAS
SISTEMA DE BIBLIOTECAS DA UNICAMP
REPOSITÓRIO DA PRODUÇÃO CIENTÍFICA E INTELLECTUAL DA UNICAMP

Versão do arquivo anexado / Version of attached file:

Versão do Editor / Published Version

Mais informações no site da editora / Further information on publisher's website:

https://journals.lww.com/hemasphere/fulltext/2023/08003/p1199__clinical_upshots_of_pioneer_project_to.1097.aspx

DOI: <https://doi.org/10.1097/01.hs9.0000971692.23451.32>

Direitos autorais / Publisher's copyright statement:

©2023 by Wolters Kluwer Health. All rights reserved.

DIRETORIA DE TRATAMENTO DA INFORMAÇÃO

Cidade Universitária Zeferino Vaz Barão Geraldo

CEP 13083-970 – Campinas SP

Fone: (19) 3521-6493

<http://www.repositorio.unicamp.br>

P1199 CLINICAL UPSHOTS OF PIONEER PROJECT TO COLLECT DATA OF T-CELL NHL PATIENTS AMONG FIVE REGIONS OF BRAZIL. T-CELL BRAZIL PROJECT.

Topic: 19. Aggressive Non-Hodgkin Lymphoma – Clinical

Carlos Sergio Chiattoni^{1,2}, Eliana Miranda³, Juliana Pereira⁴, Karin Cecyn⁵, Sergio Brasil², Nelson Castro⁶, Renata Lyrio Rafael Baptista^{7,8}, Marcelo Bellesso⁹, Danielle F C De Farias¹⁰, Davimar Miranda Maciel Borducchi¹¹, Guilherme Duffles³, Jamila Vaz Tavares¹², Yung Bruno De Mello Gonzaga¹³, Carolina Colaco Villarim¹⁴, Cláudio César Gomes De Macedo¹⁴, Gilnara Fontinelle¹⁵, Maria Almeida Dias¹⁶, Patricia De Paulo Giacon Radtke¹⁷, Diego Vila Cle¹⁸, Ademair Dantas Da Cunha Júnior¹⁹, Samir Nabhan²⁰, Frederico Lisboa Nogueira²¹, Natalia Zing²², Sergio Araujo²³, Rony Schaffel²⁴, Elizete Negreiros²⁵, Joao Tadeu Souto Filho²⁶, Vera Lucia Figueiredo²⁷, Rafael Gaiolla²⁸, Mateus Dal Pont²⁹, Fernando Barroso³⁰, Renata Rolim De Souza³⁰, Nelson Hamerschlag³¹, Suellen Gi Mo¹, Eduardo Ribeiro³², Abrahão Hallack-Neto³³, Yana Rabelo³⁴, Milene Abdo L Matedi³⁵, Thais Fischer³⁶, Guilherme Fleury Perini³⁷, Nadjanara D Bueno³⁸, Priscilla Cury³⁹, Marcia T Delamain⁴⁰, Massimo Federico⁴¹, Carmino A De Souza³

¹Oncology Nucleus, Samaritano Hospital, Higienópolis, Sao Paulo, Brazil; ²Hematology Department, Santa Casa Medical School Of São Paulo, Sao Paulo, Brazil; ³Hematology And Hemotherapy Center, University Of Campinas – Unicamp, Campinas, Brazil; ⁴Laboratory Of Medical Investigation In Pathogenesis And Directed Therapy In Onco-Immuno-Hematology, Medicine School Of University Of São Paulo -Usp, Sao Paulo, Brazil; ⁵Hematology Department, Federal University Of Sao Paulo – Unifesp, Sao Paulo, Brazil; ⁶Hematology Department, Hospital De Cancer De Barretos, Hospital De Amor, Barretos, Brazil; ⁷Hematology Department, Hu Da Universidade Estadual Do Rio De Janeiro – Uerj, Rio De Janeiro, Brazil; ⁸Hematology Department, Instituto D'Or De Pesquisa E Ensino (Idor), Rio De Janeiro, Brazil; ⁹Hematology Department, Hemomed, Instituto De Ensino E Pesquisa – Iep, São Lucas, Sao Paulo, Brazil; ¹⁰Hematology Department, Hospital Beneficencia Portuguesa De Sp, Sao Paulo, Brazil; ¹¹Hematology Department, Faculdade De Medicina Do Abc (Fmabc), Santo Andre, Brazil; ¹²Hematology Department, Hospital Ophir Loyola, Belem, Brazil; ¹³Hematology Department, National Cancer Institute – Inca, Rio De Janeiro, Brazil; ¹⁴Hematology Department, Instituto De Ensino, Pesquisa E Inovação, Liga Contra O Câncer, Ceca, Natal, Brazil; ¹⁵Hematology Department, Hospital Aldenora Bello, São Luis, Sao Luis, Brazil; ¹⁶Hematology Department, Hu Da Universidade Federal Da Bahia – Ufba, Salvador, Brazil; ¹⁷Hematology Department, Casa De Saude Santa Marcelina, Sao Paulo, Brazil; ¹⁸Hematology Department, Medical School Of Ribeirao Preto, University Of São Paulo, Usp-Ribeirao Preto, Ribeirão Preto, Brazil; ¹⁹Hematology And Oncology Clinics, Cancer Hospital Of Cascavel – Uopecan, Cascavel, Brazil; ²⁰Hematology Department, Federal University Of Paraná, Ufpr, Curitiba, Brazil; ²¹Hematology Department, Hospital Luxemburgo, Instituto Mario Penna, Belo Horizonte, Brazil; ²²Hematology Department, Prevent Senior, Sao Paulo, Brazil; ²³Hematology Department, Hc Da Universidade Federal De Minas Gerais – Ufmg, Belo Horizonte, Brazil; ²⁴Hematology Department, Hospital Universitario, Universidade Federal Do Rio De Janeiro – Ufrj, Rio De Janeiro, Brazil; ²⁵Hematology Department, Hospital De Amor Amazônia, Fundação Pio Xii, , Porto Velho, Brazil; ²⁶Hematology Department, Faculdade De Medicina De Campos, Campos De Goytacazes, Brazil; ²⁷Hematology Department, Instituto De Assistência Médica Ao Servidor Público Estadual De S. Paulo – Iamspe, Sao Paulo, Brazil; ²⁸Hematology Department, Medical School Of Sao Paulo State University, Unesp, Botucatu, Brazil; ²⁹Centro De Pesquisas Oncológicas – Cepon, Florianópolis, Brazil; ³⁰Hematology Department, Hospital Universitário Walter Cantídio, Ufpe, Fortaleza, Brazil; ³¹Hematology Department, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ³²Hematology Department, Hospital Santa Lucia, Brasília, Brazil; ³³Hematology Department, Hu Da Universidade Federal De Juiz De Fora – Ufjf, Juiz De Fora, Brazil; ³⁴Hematology Department, Hc Da Universidade Federal De Goiás – Ufgo, Goiania, Brazil; ³⁵Hematology Department, Santa Casa De Belo Horizonte, Belo Horizonte, Brazil; ³⁶Hematology Department, Ac Camargo Hospital Cancer Center, Sao Paulo, Brazil; ³⁷Hematology Department, Hospital Paulistano, Oncologia Américas, Sao Paulo, Brazil; ³⁸Frad Clinica Medica, Santo Andre, Brazil; ³⁹Clinica São Germano, Sao Paulo, Brazil; ⁴⁰Teaching Department, Medical School Of Minas Gerais – Fcmmg, Belo Horizonte, Brazil; ⁴¹Oncology And Hematology Department, University Of Modena And Reggio Emilia, Modena, Italy

Background:

In western countries, non-Hodgkin's lymphomas of peripheral T-cells (PTCL) represent about 12% of all NHL. In Brazil, the National Institute of Cancer (INCA) estimates for the years 2023/2024/2025 about 12,040 new cases of

Copyright Information: (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

NHL, which would result in a just over 1,444 new cases of T-cell NHL peripheral. Brazil T-cell project is a study to collect data from all five macro regions of Brazil, in the period of January 2015 to December 2022.

Aims:

The main goal is to collect epidemiological and clinical data from the most frequent subtypes of PTCL investigating the clinical and biology characteristics and to create a routine pathological revision.

Methods:

Ambispective and observational study involving 570 Brazilian patients with PTCLs among 39 centers. OS and PFS curves were calculated by the Kaplan-Meier Method and Log-Rank test to compare their curves. Statistical analysis was performed using IBM-SPSS v.24 software and P-values $\leq 5\%$ were considered statistically significant.

Results:

A total of 597 patients were registered, 570 (95.5%) were analyzed until now, 13 excluded and 14 due to incomplete data. Median age of 52 years (18-92), 58% male. PTCL-not otherwise specified (PTCL-NOS, n=174, 30.5%) was the most common subtype, followed by ALK-negative ALCL (ALCL, ALK-, n=102, 18%), Adult T-cell (ATL, n=87, 15%), Extranodal natural killer (ENKTL-NT, n=75, 13%), angioimmunoblastic (AITL, n=58, 10%), ALK-positive (ALCL, ALK+, n=36, 6%) and others (n=38, 7.5%). Almost 71% of patients had stage III or IV; 61% B symptoms; 70% lymph nodes and 54% extranodal involvement; 5.5% had CNS infiltration. The most upfront use of chemotherapy was 49% CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone) and 21.5% CHOP (CHOEP except etoposide). 13% used radiotherapy and 14% were submitted to stem cell transplantation as consolidation. The best response (complete and partial) was reached by 40% and 14%, however, it was undetermined by 14% due to early death. At moment of this analysis, there were 253 (44%) of deaths, 59% by lymphoma, 25.5% infection, 7.5% toxicities, 7% undetermined and 1% new neoplasia. The median overall survival (OS) was 11 months for all and 21 months for alive cases. 24-month PFS was 36% (95% CI: 32-40%) whereas 24-month OS was 50% (95% CI: 46-54%). 24-month OS by main subtypes was: 82% ALCL, ALK+; 62% ALCL, ALK-; 49% ENKTL-NT; 48% PTCL-NOS; 34% AITL and 33% ATL.

Summary/Conclusion:

This is the first experience cover all over the country, focusing also an educational and of interchanging experience network among the multidisciplinary health team in Brazil. This study has given an opportunity to understand better the relative frequency of each subtype of PTCLs geographically, the preferred treatments, even their results. Besides that, we will have the chance to check and analyze the pathological review results crossing with clinical and treatment outcomes.

Copyright Information: (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.